Dabur India Ltd Q1 FY27 Earnings Call: Guides Double-Digit Revenue Growth, Targets Accretive Profit Growth

Dabur India Ltd held its Q1 FY27 earnings call on July 29, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Growth Delivers Beat Across Revenue, Margin & Profit

• Consolidated revenue grew 10.6% in Q1 FY 2026-2027, driven by broad-based growth across India and international businesses, with operating profit (11%) and PAT (15%) both growing ahead of the top line.
• India FMCG revenue grew 9.5% in Q1 FY 2026-2027, with volume growth of 5%; International business grew 15.5% in INR terms, providing a meaningful growth differential.
• Operating margin grew 11% and PAT increased 15% in Q1 FY 2026-2027, reflecting operating leverage and margin-accretive category mix despite input cost headwinds.
• Management expects sequential acceleration in revenue growth in coming quarters of FY 2026-2027, supported by stable consumption, go-to-market transformation, premiumization, and innovation pipeline.

HPC, Foods & Beverages Deliver Double-Digit Growth; Herbal Outperformance Continues

• HPC portfolio grew 12.3% in Q1 FY 2026-2027; hair oil portfolio delivered high-teens value growth with 102 bps market share gain, while the hair oil segment overall posted 18% value growth (~50% from price increases linked to LLP/crude oil inflation).
• Oral care delivered near double-digit growth in Q1 FY 2026-2027, with the herbal segment outperforming non-herbal by 550 bps, reinforcing Dabur's differentiation in the natural/ayurvedic positioning.
• Honitus (OTC) registered 25% growth in Q1 FY 2026-2027; health juices grew mid-20s; new nutraceutical brand Sign grew 3x, reflecting strength in the health & immunity platform.
• Active juices grew over 40% (market share gain of 600 bps); coconut water grew over 70% (gain of 344 bps); foods business grew ~30% in Q1 FY 2026-2027, driven by distribution expansion and category building.
• Badshah delivered 13.3% revenue growth in Q1 FY 2026-2027 (~11% volume growth, no price increase); post-acquisition annualized run-rate increased from ~Rs.220 Cr to ~Rs.400 Cr as of Q1 FY26-27, with international markets growing >40%.
• Glucose and juice categories recovered after a weak April in Q1 FY 2026-2027: glucose saw mid-teens growth in May and high-teens in June; 100% juices grew ~45%, fizz portfolio ~30-35% in the quarter.

Double-Digit Growth Across Key Geographies; Currency Tailwinds in MENA

• MENA grew 9%, UK/EU 22%, Egypt 28%, Turkey 27%, and Bangladesh 34% in INR terms in Q1 FY 2026-2027, demonstrating broad-based momentum across both developed and emerging markets.
• International business provides a tailwind from currency upside in dollar-denominated Middle East markets, supplementing organic growth in the region.
• Badshah international markets grew >40% in Q1 FY 2026-2027, contributing to the brand's overall run-rate expansion and regional diversification beyond India.
• Overall International business grew 15.5% in INR terms in Q1 FY 2026-2027, outpacing domestic growth and supporting consolidated margin structure.

Rs.500 Cr D2C Acquisition Fund, New Brand Pipeline & Distribution Moat

• Management has earmarked Rs.500 Cr for D2C acquisitions via the Dabur Ventures fund, targeting one or two sizable acquisitions over the next three years; strategy involves taking minority stakes, helping turn profitable, then moving to majority — discussions with two to three companies are ongoing.
• The Science brand (nutraceuticals/D2C) launched late FY 2025-2026; management expects an annualised revenue run-rate (ARR) exit of ~Rs.50 Cr by end of FY 2026-2027, validating the incubate-and-scale model.
• New India CEO Harjeet Bhalla (appointed three months ago) cited iconic brands, distribution moat, people passion, and consumer trust as key competitive strengths; results consistency over the last three quarters noted as a positive signal.
• E-commerce and quick commerce now contribute 6% of Badshah turnover and are growing at triple digits, indicating successful digital channel penetration for a traditionally offline brand.
• Disruptive innovation highlighted as a growth pillar; management expects sequential revenue acceleration in coming quarters of FY 2026-2027 supported by premiumization and new product launches.

Double-Digit Revenue Guidance Maintained; Inflation & Geopolitical Risks Watched

• Management maintains double-digit revenue growth guidance for consolidated business for full-year FY 2026-2027, despite inflationary pressures, citing brand strength for price pass-through and vigilant monitoring of Middle East conflict.
• Profit growth for FY 2026-2027 is targeted to be accretive to top-line growth, but the outlook is conditional on geopolitical stability — if the war ends, crude-linked inflation would moderate; otherwise a "wait and watch" approach applies.
• Volume growth under pressure in FY 2026-2027; growth is expected to be driven more by price/value mix due to rising inflation, with hair oil already showing ~50% of value growth from price increases.
• Cash and investments stand at ~Rs.9,000 Cr (~Rs.6,500 Cr in India); capital allocation priorities are M&A (mid-to-large or D2C via the Rs.500 Cr Dabur Ventures fund), dividends (100% of India profits returned), and capex of Rs.400-500 Cr for the Tamil Nadu plant.
• Dividend payout increased to 75-80% of PAT over the last two years; an analyst suggested that "a formal capital allocation policy at board level could benefit investors" to provide clearer visibility on surplus deployment.
• Rural demand grew ahead of urban by 170 bps (Nielsen category) and 550 bps (Dabur GT, excluding modern trade/e-commerce) in Q1 FY 2026-2027, underscoring resilience in the rural franchise.
• Monsoon deficit narrowed to 14-15% in the last fortnight, easing fears of Kharif output impact; management sees this as manageable for FY 2026-2027.